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What is GeneLab?
• Currently, GeneLab is a (1) data repository that hosts space biology 
datasets, (2) a collaborative workspace for users to share files and 
access data analysis tools, and (3) workspace to do metadata 
curation.
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What is GeneLab?
Ultimately, GeneLab aims to provide a 
single platform where users can capture, 
curate, store, search, share, transfer, 
analyze and visualize spaceflight 
datasets.
What is GeneLab?
Overall, the goal of GeneLab is to allow for better understanding of the 
impact of spaceflight on biology!
What Already Exists on GeneLab 
Database: 154 data sets
Majority is spaceflight samples Distribution by assay type
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• Overall goal is to allow for better understanding of the impact of 
spaceflight on biology using publicly available omics data
– Generate Hypothesis to direct future experimental research
– Determine acceptable health risks for long-term space missions
– Develop potential countermeasures against 
• A rich resource for both the scientific and non-scientific community to 
explore questions they have on space biology.
• A platform which can be used by both advanced and basic users to 
explore all omics data.
Overall Goal of GeneLab
• Systems biology attempts to understand biological organisms
or systems as a whole rather than researching their individual
components in isolation from one another.
• NIH defines Systems Biology as: “Systems biology is an
approach in biomedical research to understanding the larger
picture—be it at the level of the organism, tissue, or cell—by
putting its pieces together. It’s in stark contrast to decades of
reductionist biology, which involves taking the pieces apart.”
What is Systems Biology?
Hypothesis generation from GeneLab 
Data
Number of Significant Genes from 
Multiple Datasets
Predicted Master Regulators
Predicted Master Regulators
• p53 found in all tissues
• p53 is a transcription factor and in 
response to genotoxic stress, DNA 
damage, oncogene activation, and 
hypoxia, it is recruited to sites in 
chromatin, thus promoting transcription 
of apoptosis related genes 
Determination of Key 
Genes/Drivers
Beheshti, et al. Cancer Research 2015
Beheshti, et al. Oncotarget 2015
Beheshti, et al. Cancer Informatics 2015
Beheshti, et al, Radiat Res. 2014 & J. Radiat Res. 2015.
Ravi, Beheshti, et al. Cancer Research 2016
Key Genes and the Connections
Key Genes and the Connections
• TGFβ1 found to be central regulator of key genes
• TGFβ is known to play a context specific role in
sustaining tissue homeostasis predominantly via
transcriptional regulation of genes involved in
differentiation, cell motility, proliferation, cell survival
along with regulating immune responses during
homeostasis and infection.
• Previous Studies found reduction in gravitational force
to diminish TGF-β expression and apoptosis with higher
carcinoembryonic antigen expression in 3D human
colorectal carcinoma cells, as compared to 3D cultures
in unit gravity.
• In another study, differential regulation of blood vessel
growth using basic fibroblast growth factor was
identified in modeled microgravity with induction early
and late apoptosis, extracellular matrix proteins,
endothelin-1 and TGFb1 expression
Generating a Hypothesis from GeneLab
Analysis
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Analysis
Circulating miRNAs
Revised View of Molecular Biology
• A single miRNA has been estimated to regulate up to 500 mRNAs
• miRNAs are single-stranded RNA sequences, of about 22 nucleotides in 
length, processed from longer transcripts. 
• miRNAs are important regulators that repress the translation of mRNA 
transcripts
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• A recent report showed that inactivation of p53 altered TGF-β signaling, which
ironically displayed both tumor-suppressive and pro-oncogenic functions. p53
functions to integrate crosstalk between Ras/MAPK and TGF-β signaling via
binding to Smad3, dislocating the Smad3/Smad4 complex formation and
differentially regulating subsets of TGF-β target genes
Using OpenTarget to Generate 
Countermeasures
Key Genes for individual 
tissues
Output of OpenTarget
Steps to Determine Potential Drugs for 
Countermeasures
1. Determine drugs targets for each tissue 
from “key genes”
Tissues/datasets that provided 
a list of drug hits from the key 
genes: RR1: Soleus muscle, 
RR1: Quadricep, RR1: 
gastrocnemius, RR1: extensor 
digitorum longus, RR1: Tibialis 
Anterior, GLDS-21: skeletal 
muscle , GLDS-62: Skin, RR1: 
adrenal gland, RR1: Kidney, 
GLDS-4: Thymus, RR1: Liver, 
GLDS-25: Liver
2. Find common drugs targets that exist between all the tissues
Information of Common Drugs
Drugs Target Common Prediction Status Terminated
UCN-01 PRKCQ 6 Y Completed N
MIDOSTAURIN PRKCQ 5 Y Active. Recruiting N
DACTOLISIB PIK3CD 5 Y Withdrawn, Terminated, Completed Y
PICTILISIB PIK3CD 5 Y Completed, terminated, recruiting Y
GSK-690693 PRKCZ 4 Y Withdrawn, Terminated Y
APITOLISIB PIK3CD 5 N Completed, active N
BGT-226 PIK3CD 5 N Completed N
DS-7423 PIK3CD 5 N Completed N
RG-7666 PIK3CD 5 N Completed N
SF-1126 PIK3CD 5 N Recruiting, completed N
TASELISIB PIK3CD 5 N Completed, Active, recruiting N
VOXTALISIB PIK3CD 5 N Completed N
ZSTK-474 PIK3CD 5 N Completed N
BUPARLISIB PIK3CD 5 N Completed, active, withdrawn, recruiting, terminated, recruiting Y
COPANLISIB PIK3CD 5 N Suspended, terminated, recruiting, active, completed Y
GEDATOLISIB PIK3CD 5 N Terminated, recruiting, active, completed Y
GSK-1059615 PIK3CD 5 N Terminated Y
PF-04691502 PIK3CD 5 N Withdrawn, Terminated, Completed Y
VS-5584 PIK3CD 5 N Terminated Y
WX-037 PIK3CD 5 N Terminated Y
LY-3023414 PIK3CD 5 ? Recruiting N
OMIPALISIB PIK3CD 5 ? Completed N
PA-799 PIK3CD 5 ? Completed N
PILARALISIB PIK3CD 5 ? Completed N
Sonolisib PIK3CD 5 ? Completed N
ENMD-981693 HCK 4 ? Completed N
Panulisib PIK3CD 5 ? Suspended Y
SOTRASTAURIN PRKCQ 4 N Terminated, completed, recruiting Y
Two possible drug candidate for 
countermeasures against Spaceflight
• Also known as: 7-hydroxystaurosporine
• Inhibits many phosphokinases, including the serine/threonine kinase 
AKT, calcium-dependent protein kinase C, and cyclin-dependent kinases
– arrests tumor cells in the G1/S of the cell cycle and prevents nucleotide 
excision repair by inhibiting the G2 checkpoint kinase chk1, resulting in 
apoptosis
– Phase 1 and 2 clinical trails with drug for various cancers (information available 
on ClinicalTrials.gov)
• Pancreatic Cancer: Completed, No results listed
• Small Cell Lung Cancer: Completed, Response rate: 2/19 patients with CR or PR and 
9/19 with Stable Disease
• Melanoma: Terminated, early termination for discouraging results
• Lymphoma, Terminated, due to low accrual and cost
• Kidney Cancer: Completed, No results listed
• Advanced Solid Tumors: Completed, No results listed
Two Drug Candidates: UCN-01
• (sold under the name Rydapt) is a multi-targeted protein kinase inhibitor
that has been investigated for the treatment of acute myeloid leukemia
(AML), myelodysplastic syndrome (MDS) and advanced systemic
mastocytosis.
• It is a semi-synthetic derivative of staurosporine, an alkaloid from the
bacterium Streptomyces staurosporeus.
• a multikinase inhibitor for oral use
• a small molecule that inhibits multiple receptor tyrosine kinases
– inhibit the activity of wild type FLT3, FLT3 mutant kinases (ITD and TKD), KIT
(wild type and D816V mutant), PDGFRα/β, VEGFR2, as well as members of the
serine/threonine kinase PKC (protein kinase C) family.
– Midostaurin demonstrated the ability to inhibit FLT3 receptor signaling and cell
proliferation, and it induced apoptosis in leukemic cells expressing ITD and TKD
mutant FLT3 receptors or overexpressing wild type FLT3 and PDGF receptors
• Approved FDA drug (2017)
Two Drug Candidates: Midostaurin
• Both UCN-01 and midostaurin inhibit cytosolic PKC
– Jirousek & Goekjian, Expert Opin Investig Drugs. 2001 Dec;10(12):2117-40
• Can these anti-cancer drugs be applied to the negative health effects 
associated with long term space missions?
– Midostaurin has been shown to improve Bone Loss effects
• Brounais et al, Clin Cancer Res. 2008 Sep 1;14(17):5400-9. doi: 10.1158/1078-
0432.CCR-07-4781.
– Inhibiting FLT3 (inhibited by Midostaurin) can prevent immune related 
effects due to spaceflight
• Whartenby et al, Expert Opin Investig Drugs. 2008 Nov; 17(11): 1685–1692.
• Inhibiting PKC (by Midostaurin and UCN-01) has beneficial effects with 
space related health risks
– Can impact diabetic complications, heart failure, myocardial infarction, pain 
and bipolar disease 
• Mochly-Rosen et al, Nat Rev Drug Discov. 2012 Dec; 11(12): 937–957.
• There are possible examples of how these two drugs can be 
adapted as a potential countermeasure
UCN-01 and Midostaurin and potential 
countermeasure use
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Questions and Discussion???
